Antimicrobial Resistance Market Expected to Reach $9.5 Billion by 2032—Allied Market Research

According to a new report published by Allied Market Research, titled, “Antimicrobial Resistance Market," The antimicrobial resistance market size was valued at $4.6 billion in 2022, and is estimated to reach $9.5 billion by 2032, growing at a CAGR of 7.6% from 2023 to 2032. Antimicrobial resistance may be defined as the resistance offered by the pathogens to the class of drugs. The spread of drug-resistant bacteria that have developed new resistance mechanisms is leading to antimicrobial resistance globally.

Moreover, spread of multidrug-resistant bacteria and superbugs at an alarming rate has increased the global AMR burden. To overcome this resistance there is an urgent need to develop novel antimicrobials which are highly effective against these resistant microbes, which proves to be the major factor among the antimicrobial resistance market trends. 

The antimicrobial resistance market analysis is done on the basis of drug class, pathogen, indication, mechanism of action and region. On the basis of drug class, the market is categorized into combination therapies, oxazolidinones, glycopeptides and lipoglycopeptides, tetracyclines, cephalosporins and others. The combination therapies segment held a major antimicrobial resistance market share in 2022 which is attributed to the availability of a significant range of novel antibiotics combination for the treatment of severe bacterial infections. For instance, Zerbaxa, Avycaz, Vabomere, Recarbrio and others are a few of the combination antibiotics available in the market. 

On the other hand, the others segment is anticipated to be the fastest growing segment during the forecast period. This growth is attributed to the strong novel antibiotic pipeline belonging to the class such as macrolides, and others. In addition, there is a rise in funding for development of new novel antibiotics which is anticipated to drive the market growth during the antimicrobial resistance market forecast period. 

On the basis of indication, the market is segmented into complicated urinary tract infections (cUTI), acute bacterial skin and skin structure infections (ABSSSI), hospital-acquired bacterial pneumonia and ventilator acquired bacterial pneumonia (HABP & VABP), community-acquired pneumonia (CABP), bloodstream infections and others. The complicated urinary tract infections (cUTI) segment had a major share of the antimicrobial resistance market size in 2022, which is attributed to the rise of antimicrobial resistance (AMR) among uropathogenic bacteria that has rendered some traditional antibiotics less effective in treating cUTIs. This challenges healthcare providers to seek alternative treatment strategies and more potent antibiotics.

On the other hand, hospital-acquired bacterial pneumonia, and ventilator-acquired bacterial pneumonia (HABP and VABP) segment is anticipated to be the fastest-growing segment during the forecast period. This is attributed to the rise in healthcare related infections among the people admitted to hospitals. In addition, mechanical ventilation, while essential in critical care, may introduce bacteria into the lower respiratory tract, leading to VABP which further increases the demand for novel antibiotics. 

On the basis of pathogen, the market is segmented into E. coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus, Enterococcus Spp, and others. The E. coli segment held a major antimicrobial resistance market share owing to the rising resistance of E coli species to multiple drugs and launch of novel antibiotics to overcome this threat. According to the WHO the resistance to fluoroquinolone antibiotics in E. coli, used for the treatment of urinary tract infections, is widespread and this treatment is ineffective in more than half of patients in many countries around the globe. Hence, there is a significant need for development of novel antibiotics which may overcome the resistance caused by E coli. 

On the other hand, the klebsiella pneumoniae segment is anticipated to be the fastest growing segment during the forecast period. This is mainly attributed to the rise in antimicrobial resistant bacterial infections caused by klebsiella pneumoniae such as hospital-acquired bacterial infections. Moreover, significant product development to treat antimicrobial resistant klebsiella infections has contributed to the growth of antimicrobial resistance industry. 

On the basis of mechanism of action, the market is segmented into protein synthesis inhibitors, cell wall synthesis inhibitors and others. The cell wall synthesis inhibitors segment dominated the market in 2022 and is anticipated to be the fastest growing segment during the forecast period. This is attributed to the development of novel antibiotics by the key players which mainly act on the cell wall of the bacteria. In addition, the launch of a significant number of novel antibiotics with cell wall synthesis inhibitory actions such as Avycaz, Vabomere and Recarbrio has contributed to the growth of the segment. 

On the basis of region, North America had the highest market share in 2022 and is expected to maintain its lead during the forecast period owing to the significant incidence of antimicrobial resistance in this region, along with rising awareness among the people for appropriate use of antibiotics. However, Asia-Pacific is expected to exhibit the fastest growth during the forecast period, owing to a huge burden of AMR in populated countries such as China and India and rising investments by the key players to develop novel antibiotics to overcome AMR. 

Key findings of the study

•On the basis of drug class, combination therapies segment dominated the market in 2022.

•On the basis of indication, complicated urinary tract infections (cUTI) segment dominated the antimicrobial resistance industryin 2022.

•On the basis of pathogen, E. coli segment dominated the market in 2022.

•On the basis of mechanism of action, cell wall synthesis inhibitors segment dominated the market in 2022.

•On the basis of region, North America dominated the market in 2022. However, Asia-Pacific is the fastest-growing segment during the forecast period.